Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 21, 2007; 13(39): 5238-5244
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5238
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5238
Figure 1 Patients observed at 12-mo intervals (endpoints) during IFX maintenance therapy.
A: CD; B: UC. Numbers in boxes refer to patients reaching each endpoint. Numbers in rhombics refer to patients not reaching 12-mo endpoints.
Figure 2 Kaplan-Meier survival curve for CD patients (n = 40).
The cumulative probability of being free of relapse in CD patients with complete response was: 97.2% (CI: 91.8%-100%) at 12 mo, 90.3% (CI: 79.7%-100%) at 24 mo, 81.7% (CI: 66.9%-96.5%) at 36 mo, 73.5% (CI: 53.3%-93.7%) at 48 mo, and 61.3% (CI: 33.6%-88.9%) at 51 mo.
- Citation: Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244
- URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5238.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i39.5238